论文信息 - Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM. - 字舞流文

Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.

T. Zander | E. Maiello | R. Hofheinz | D. Strumberg | S. Al-Batran | T. Gaiser | D. Pink | E. Goekkurt | T. Goetze | C. Pauligk | G. Siegler | J. Potenberg | F. De Vita | N. Homann | H. Kopp | D. Sookthai | M. Schenk | H. Schmalenberg | S. Angermeier | Tanita Brulin | T. Brulin